Pimavanserin for the Treatment of Alzheimer’s Disease Psychosis: An Evaluation of the Clinical Importance of Efficacy Results

Clive Ballard, Jeffrey Cummings, Pierre N Tariot, Sanjeev Pathak, Bruce Coate, Srdjan Stankovic
doi: https://doi.org/10.1101/2022.08.11.22278482

Article Information

doi 
https://doi.org/10.1101/2022.08.11.22278482
History 
  • August 12, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Clive Ballard1,
  2. Jeffrey Cummings2,
  3. Pierre N Tariot3,
  4. Sanjeev Pathak4,*,
  5. Bruce Coate4 and
  6. Srdjan Stankovic4
  1. 1University of Exeter Medical School, Exeter, UK
  2. 2Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA
  3. 3Banner Alzheimer’s Institute and University of Arizona College of Medicine, Phoenix, AZ, USA
  4. 4Acadia Pharmaceuticals Inc., San Diego, CA, USA
  1. ↵* Corresponding author; email: sanjeev.pathak{at}acadia-pharm.com
Back to top
Posted August 12, 2022.
Download PDF
Data/Code
Email
Pimavanserin for the Treatment of Alzheimer’s Disease Psychosis: An Evaluation of the Clinical Importance of Efficacy Results
Clive Ballard, Jeffrey Cummings, Pierre N Tariot, Sanjeev Pathak, Bruce Coate, Srdjan Stankovic
medRxiv 2022.08.11.22278482; doi: https://doi.org/10.1101/2022.08.11.22278482
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area